A non-randomized, open-label, parallel-controlled pharmacokinetic and safety study of XY0206 tablets in participants with mild to moderate hepatic insufficiency and healthy participants.

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: f0cd53d497c318d170a5936197cae6c4a9357039
First added on: Oct 10, 2026